Joshua M Hare
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Joshua M Hare sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Joshua M Hare: 10 sponsored US clinical trials, 1 recruiting.
Joshua M Hare sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-ischemic Dilated Cardiomyopathy, with 1 trials.
Top-decile sponsor footprint
Joshua M Hare ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
NCT04476901
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)
NCT04776239
The CHILD Trial: Hypoplastic Left Heart Syndrome Study.
NCT03406884
Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.
NCT03059355
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
NCT02675556
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
NCT02886884
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
NCT02013674
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
NCT02013700
PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)
NCT01392625
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
NCT00587990
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Joshua M Hare pipeline
1 recruiting of 10 indexed (10% open); 5 completed (50%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Non-ischemic Dilated Cardiomyopathy (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Joshua M Hare: open-pipeline peers nationwide
Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Joshua M Hare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Abiomed · 10% recruiting · 20 trials
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
Related
What to do with this Joshua M Hare page
10 registered trials is a research-attention snapshot, not an endorsement of Joshua M Hare or any single study.
- 1 of Joshua M Hare's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-ischemic Dilated Cardiomyopathy is the condition Joshua M Hare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-ischemic Dilated Cardiomyopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Joshua M Hare pipeline card: 10 registered trials from official public datasets.Report a data error.